In an attempt to identify markers of resistance to trastuzumab, we evaluated both the profiling of human epidermal growth factor receptor 2 (HER2)-positive tumor cells measuring the relative levels of EGFR, pMAPK, pAkt and PTEN and their correlations with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab.
introduction
The humanized mAb trastuzumab was developed as a therapy targeted against the human epidermal growth factor receptor 2 (HER2), which is overexpressed in 20%-25% of invasive breast cancer and is associated with poor prognosis. Overexpression and/or gene amplification of HER2 in tumor tissue are predictive factors of therapeutic benefit from trastuzumab [1] .
Trastuzumab alone or in combination with chemotherapy has been shown to be an active therapy in HER2-positive metastatic breast cancer patients [2] [3] [4] . However, many patients have shown 'primary' (de novo) resistance to trastuzumab administered as a single agent [2] or in association with taxanes [3, 4] . Median time to disease progression was 4.9 months with trastuzumab monotherapy [2] and 7.4-9.8 months when combined with paclitaxel [3] or docetaxel [4] , respectively. Thus, the most of patients who have an initial response to trastuzumab-based regimens develop 'acquired' resistance within 1 year.
Hence, in addition to protein overexpression and gene amplification of HER2, it seems important to find additional predictive markers of response to select patients who would benefit from this treatment. Defining the molecular mechanisms of action of trastuzumab and of resistance to HER2-blockade may provide insight into the optimal clinical use of this targeted therapy.
Unfortunately, the trastuzumab's 'mechanisms of action' have not been fully characterized and appear to be complex [5] and the 'mechanisms of resistance' to trastuzumab are still poorly understood. Except for HER3, all the other members of the HER family have intrinsic tyrosine kinase activity, and all, with the exception of HER2, bind to specific ligands via their extracellular domain. Upon ligand binding, the receptors dimerize using HER2 as their preferred binding partner [6] . Heterodimers and homodimers induce intrinsic receptor tyrosine kinase activity and subsequent activation of downstream signaling components via the MAPK (proliferation pathway) and PI3K-Akt (survival pathway) cascades. Although trastuzumab reduces HER2-mediated signaling through these pathways, it may not reduce signaling mediated from other HER receptors. Therefore, cells with EGFR/EGFR or EGFR/HER3 heterodimers may initiate mitogenic PI3K-Akt and MAPK signaling even in the presence of trastuzumab [7] . Structural studies [8] have indicated that trastuzumab binds to a region of HER2 receptor ectodomain not involved in receptor dimerization and so trastuzumab is unable to block ligand-induced EGFR/HER2 and HER2/HER3 (among the most potent activators of the PI3K-Akt pathway) heterodimers [9] .
Thus, the determination of the relative levels of EGFR in HER2-positive tumor cells could be useful for predicting resistance to trastuzumab.
PTEN is a dual phosphatase, with membrane localization, which antagonizes PI3K (phosphatidylinositol 3-kinase) function and inhibits Akt activities (cell survival pathway) and tumor growth [10] . Preclinical data have shown that PTEN is functionally inactivated in HER2-overexpressing cancer cells [10] .
Recently, Nagata et al. [11] have demonstrated, in preclinical setting and in a retrospective series of HER2-overexpressing breast cancers treated with trastuzumab and taxane, that PTEN activation (by increasing the translocation of PTEN from the cytoplasm to the membrane) seems to be a novel mechanism underlying trastuzumab's activity and PTEN loss could render HER2-overexpressing breast cancer resistant to trastuzumabbased therapy [12] .
In an attempt to identify markers of resistance to trastuzumab, we evaluated the profiling of HER2-positive tumor cells measuring the relative levels of EGFR, pMAPK and pAkt ( Tumors were considered EGFR positive if the percentage of positive tumor cells was ‡1% ( Figure 1 ).
Only clear staining of the tumor cell membranes was scored positive. Diffuse cytoplasmatic or granular staining was diagnosed as negative. We also used a system that is based on staining intensity and percentage of stained cells for EGFR, as described by other authors [13] . This semiquantitative approach was used to generate a score for each tumor tissue sample: the percentage of positive tumor cells per slide (0%-100%) was multiplied by dominant intensity pattern of staining (1, negative or trace; 2, weak; 3, moderate; 4, intense). The overall score ranged from 0 to 400 and specimens were considered having levels of EGFR expression: negative or low (0-200), intermediate (201-300) and high (301-400).
Tumors were considered p-MAPK positive and p-Akt positive when the percentage of positive tumor cells was ‡10%. (Figures 1 and 2 ). Only clear staining of the tumor cell nucleus and/or cytoplasm was considered positive.
Two scoring systems for interpreting immunohistochemical staining for PTEN were used: Hirsch score [13] and Nagata score [11] . Utilizing the Hirsch score, analysis of PTEN expression was evaluated with a system based on staining intensity and percentage of stained cells [13, 14] and tumors were classified into four groups according to the PTEN protein expression (score 0-99, 100-199, 200-299 and 300-400).
When utilizing Nagata score, PTEN expression levels were also semiquantified using immunoreactive scores (IRS) calculated by multiplying the percentage of PTEN-positive cells (scored 0-4) with the PTEN staining intensity (1-3) [15] and tumors were classified using IRS <9 as criteria for PTEN loss, as previously described [11] (Figure 2 ).
statistical analysis
Complete, partial remission, stable and progressive disease were defined by World Health Organization criteria.
Time to progression (TTP) was defined as the time from the start of trastuzumab-based treatment to disease progression or death (whichever occurred first). Overall survival (OS) was defined as the time from initial diagnosis of breast cancer (OS1), from the occurrence of metastatic disease (OS2) and from the start of therapy with trastuzumab (OS3) to death from any cause. TTP and OS were determined for all patients and were estimated according to the Kaplan-Meier product limit method [16] . For all analyses, time was censored at the last follow-up date if no event/ death was observed.
Differences in time distributions were evaluated using the log-rank test [17] .
All P values are derived from two-sided significance tests. Chi-square test was used to assess the association among pathological features and response to trastuzumab, TTP, OS and central nervous system (CNS) metastases incidence. Tables 1 and 2 . Median age of patients was 53 years .
At a median follow-up of 23.0 months (range 3.7-99.6) from start of trastuzumab, 43 patients were assessable for response to trastuzumab and TTP. All patients were assessable for OS and incidence of CNS metastases. We observed 27 responses (complete + partial response) to trastuzumab-based therapy (68.9%) ( Table 3 ). Median TTP from the start of trastuzumab was 9.7 months (range 1 Table 4 . We analyzed the correlation of EGFR, pMAPK, pAkt and PTEN status with response to trastuzumab, TTP, OS (OS1, OS2, OS3) and CNS metastases incidence.
EGFR status by IHC
With a cut-off of 1%, we found nine EGFR-positive tumors (20%). EGFR status evaluated by IHC was not significantly associated with response to trastuzumab, TTP, OS (OS1, OS2, OS3) and incidence of CNS metastases. 
Annals of Oncology original article
EGFR was also evaluated by the Colorado score [13] but all patients resulted in the negative or low-level expression group (score 1-200).
pMAPK status by IHC
In our analysis, 16 tumors (35.6%) resulted pMAPK positive. pMAPK status was not significantly associated with response to trastuzumab, TTP, OS1, OS2 and CNS metastases incidence. A trend for shorter OS from the start of trastuzumab (OS3) was observed for p-MAPK-positive patients compared with pMAPK-negative patients: 22.8 months (range 3.8-99.6) versus 31.2 months (range 4.2-80); P = 0.076 (Figure 3) .
pAkt status by IHC
Twenty-three tumors were pAkt positive (51.1%). In our patients, the pAkt status of tumors evaluated by IHC was not significantly associated with response to trastuzumab, TTP and OS. However, median OS1 was shorter in 22 pAkt-positive patients (69.8 months; range 6.2-131.6) compared with 23 pAkt-negative patients (108.2 months; range 14.2-195+) (P = 0.091) (Figure 4 ). CNS metastases incidence was not correlated with pAKT status (P = 0.286).
PTEN status by IHC
We evaluated PTEN status utilizing the Hirsch score [13] and patients were classified into four groups according to the PTEN protein expression, but no differences were observed among these groups in terms of response to trastuzumab, OS and CNS metastases incidence. Patients with no or minimal PTEN expression (score 0-99) were considered as PTEN negative and patients with a score ‡100 as PTEN positive, as reported by other authors in non-small-cell lung cancer [14] . Two patients were PTEN negative (4.4%) and 43 patients (96.5%) PTEN positive. Response to trastuzumab (P = 0.047) and TTP from the start of trastuzumab were significantly worse (P = 0.002) in two patients PTEN negative. Using the Nagata score (Table 4) , original article Annals of Oncology 29 patients were classified as PTEN negative (IRS < 9) and 16 as PTEN positive (IRS ‡ 9), but no significant worse response rate to trastuzumab-based therapy was observed in the PTEN-negative patients in comparison to PTEN-positive patients (P = 0.109).
Using more stringent criteria for PTEN loss (IRS < 4), seven patients (15.6%) resulted PTEN negative and 38 (84.4%) PTEN positive, but we did not observe a significantly lower response in PTEN-negative patients as well as no correlation with TTP, OS and CNS metastases incidence was reported.
discussion
In our series of 45 HER2-positive breast cancer patients, we observed that TTP (P = 0.001) and median OS2 and OS3 were significantly longer in patients responsive to trastuzumab-based regimen compared with nonresponsive patients. About 40% of patients developed CNS metastases, with a median time of 12 months from the diagnosis of metastatic disease, as previously reported [18] .
Nine tumors resulted in EGFR positive by IHC (20%). In breast cancers unselected for HER2 status, EGFR positivity evaluated by IHC was reported in 16.4%-20.6% [19] [20] [21] while in 25%-46% of HER2-overexpressing breast cancers [20] [21] [22] . In two series, positive expression of EGFR resulted associated with HER2-positive status [20, 21] but these studies yielded unconclusive results regarding prognostic and predictive value of EGFR status in HER2-positive tumors.
EGFR status of tumor was not significantly associated with response to trastuzumab, TTP, OS and CNS metastases incidence in our series. Further studies are necessary to define the value of EGFR status in HER2-positive breast cancers.
Both pMAPK and pAkt status, evaluated by IHC, was not associated with clinical outcome, but a trend for shorter OS3 was observed for pMAPK-positive patients compared with pMAPK-negative patients (P = 0.076) (Figure 3 ). Median OS1 resulted shorter in 22 pAkt-positive patients (69.8 months; range 6.2-131.6) compared with 23 pAkt-negative patients (108.2 months; range 14.2-195+) (P = 0.091) (Figure 4 ). Being so, high expression of pMAPK (pMAPK positive) or pAkt (pAkt positive) could identify a subgroup of HER2-positive tumors with high activity of proliferation and survival pathways and with resistance to trastuzumab. To further explore this hypothesis and to evaluate the role of 'PI3K-Akt pathway' in the mechanisms of resistance to trastuzumab, we have planned to analyze the mutations of the PI3K gene (exons 9 and 20) and the overexpression of the insulin-like growth factor-I receptor, a potent inducer of PI3K and Akt [23] .
Loss of PTEN, a dual phosphatase which antagonizes PI3K function and inhibits Akt activities and tumor growth, could render HER2-overexpressing breast cancer resistant to trastuzumab-based therapy [11, 12] . The results of Nagata et al. [11] supported a role for the PI3K/Akt pathway in trastuzumab resistance. They demonstrated in vitro that when PTEN levels are low, Akt remains active and trastuzumab efficacy is impaired. In a retrospective analysis in tissues samples of 47 HER2-positive breast cancer patients who received trastuzumab plus taxane, Nagata et al. [11] observed a significantly lower response in PTEN-negative patients compared with patients with intact PTEN activity (PTEN-positive patients) . To explore the clinical significance of PTEN status in predicting response to trastuzumab-based therapy, we evaluated PTEN expression by IHC, but did not observe a significantly lower response rate in PTEN-negative patients using the Nagata score. However, using a four group classification according to PTEN protein expression (Table 4 ) and considering PTEN-negative patients with a score of 0-99, only two patients resulted PTEN negative (4.4%). In these two patients, the response rate to trastuzumab and TTP was significantly worse compared with PTEN-positive patients, but the number of PTEN-negative patients was too small to consider these results clinically relevant.
In conclusion, the evaluations of EGFR, pMAPK, pAkt and PTEN status by IHC were not significantly associated with activity and efficacy of trastuzumab in this series of HER2-positive metastatic breast cancer patients. However, possible associations cannot be excluded due to the limited number of patients enrolled and the nonstandardization of the methods.
HER2 status determined only by IHC and/or FISH assays may not be sufficient to identify tumors sensitive to trastuzumab-based therapy. Better definition of the alterations of the key signaling pathways and cell cycle/apoptosis regulator molecules that cause the transforming effects of HER2 appears to be an intriguing subject.
Hence, further studies are necessary to evaluate markers of resistance to trastuzumab and help to select the best treatment for individual patients. 
